Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
LEXINGTON, Mass., Feb. 22, 2016 -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2015 financial results on Monday, February 29, 2016, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EST to review its various pipeline programs, including CUDC-907, a dual HDAC/ PI3K inhibitor, and CA-170, an oral small molecule antagonist of PD-L1/VISTA under collaboration with Aurigene, and its partnered program, Erivedge® (vismodegib). The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2015.
To access the live conference call, please dial (877) 868-1829 from the United States or (253) 237-1135 from other locations, shortly before 8:30 a.m. EST. The conference ID number is 46140545. The conference call can also be accessed on the Curis website at www.curis.com within the Investors section.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of the PD-1 pathway/ VISTA, including PD-L1/VISTA antagonist CA-170, as well as to molecules designed to inhibit IRAK4, including CA-4948. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma and are further developing Erivedge® in other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis' website at www.curis.com.
For More Information: Mani Mohindru, Ph.D. Senior Vice President, Corporate Strategy and Investor Relations Curis, Inc. 617-503-6605 [email protected] Media Contact: David Schull Russo Partners 212-845-4271 [email protected]
